SubHero Banner

Adynovate® (antihemophilic factor [recombinant], PEGylated) – Expanded Indication

December 27, 2016 – Shire announced the FDA approval of Adynovate (antihemophilic factor [recombinant], PEGylated) injection, for use in children and adults with hemophilia A (congenital factor VIII deficiency) for on-demand treatment of bleeding and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

Download PDF